Saltar al contenido
Merck

Circulating fetuin-A predicts early mortality in chronic hemodialysis patients.

Clinical biochemistry (2009-04-04)
Vladimír Bláha, Erik Mistrík, Sylvie Dusilová-Sulková, Marta Kalousová, Ctirad Andrýs, Milan Bláha, Lubos Sobotka
RESUMEN

The purpose of this study was to assess whether low serum levels of fetuin-A are potential biochemical predictor of early and/or late survival in chronic hemodialysis (HD) patients. We measured serum levels of fetuin-A in 67 patients on chronic HD, and correlated it to 3, 12, and 24 months mortality. Cumulative death rate was 7%, 19%, and 37% deaths at 3, 12, and 24 months. Serum fetuin-A was significantly lower in 3 months and 12 months non-survivals (p<0.001), but not in 24 months non-survivals. Kaplan-Meier analyses based on fetuin-A tertiles showed statistically significantly increased probability of death up to 12 months of follow-up for decreasing fetuin-A concentrations (p<0.008). Fetuin-A as a circulating inhibitor of vascular calcification was significant predictor of early mortality in chronic HD patients but did not appear as a fair marker for later survival.